BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14722685)

  • 1. p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma.
    Samnick S; Romeike BF; Kubuschok B; Hellwig D; Amon M; Feiden W; Menger MD; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):532-41. PubMed ID: 14722685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-D-glucose in human pancreatic carcinoma xenografts and in inflammation models.
    Hellwig D; Menges M; Schneider G; Moellers MO; Romeike BF; Menger MD; Kirsch CM; Samnick S
    Nucl Med Biol; 2005 Feb; 32(2):137-45. PubMed ID: 15721759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved synthesis of no-carrier-added p-[124I]iodo-L-phenylalanine and p-[131I]iodo-L-phenylalanine for nuclear medicine applications in malignant gliomas.
    Israel I; Brandau W; Farmakis G; Samnick S
    Appl Radiat Isot; 2008 Apr; 66(4):513-22. PubMed ID: 18024046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats.
    Samnick S; Richter S; Romeike BF; Heimann A; Feiden W; Kempski O; Kirsch CM
    Eur J Nucl Med; 2000 Oct; 27(10):1543-51. PubMed ID: 11083545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Para-[(123)I]iodo-L-phenylalanine in patients with pancreatic adenocarcinoma: tumour uptake, whole-body kinetics, dosimetry.
    Hellwig D; Gouverneur E; Schaefer A; Raedle J; Menges M; Kirsch CM; Samnick S
    Nuklearmedizin; 2008; 47(5):220-4. PubMed ID: 18852930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
    Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Achten E; Dierckx RA; Mertens J; Slegers G
    J Nucl Med; 2005 Mar; 46(3):532-9. PubMed ID: 15750170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and investigation of tumor affinity, uptake kinetic and transport mechanism of iodine-123-labelled amino acid derivatives in human pancreatic carcinoma and glioblastoma cells.
    Samnick S; Schaefer A; Siebert S; Richter S; Vollmar B; Kirsch CM
    Nucl Med Biol; 2001 Jan; 28(1):13-23. PubMed ID: 11182560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative biodistribution study of the new tumor tracer [123I]-2-iodo-L-phenylalanine with [123I]-2-iodo-L-tyrosine.
    Kersemans V; Cornelissen B; Kersemans K; Dierckx RA; De Spiegeleer B; Mertens J; Slegers G
    Nucl Med Biol; 2006 Jan; 33(1):111-7. PubMed ID: 16459266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.
    Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Dierckx RA; De Spiegeleer B; Mertens J; Slegers G
    Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):919-27. PubMed ID: 16572305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation and dosimetry of 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model.
    Kersemans V; Cornelissen B; Bacher K; Kersemans K; Thierens H; Dierckx RA; De Spiegeleer B; Slegers G; Mertens J
    J Nucl Med; 2005 Dec; 46(12):2104-11. PubMed ID: 16330577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas.
    Hellwig D; Romeike BF; Ketter R; Moringlane JR; Kirsch CM; Samnick S
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):24-31. PubMed ID: 17846769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of 8-[123I]iodo-L-1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylic acid as an imaging agent for prostate cancer in experimental models of human prostate cancer.
    Samnick S; Nestle U; Wagner M; Fozing T; Schaefer A; Menger MD; Kirsch CM
    Nucl Med Biol; 2007 Jan; 34(1):99-107. PubMed ID: 17210466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial evaluation of the feasibility of single photon emission tomography with p-[123 I]iodo-L-phenylalanine for routine brain tumour imaging.
    Samnick S; Hellwig D; Bader JB; Romeike BF; Moringlane JR; Feiden W; Kirsch CM
    Nucl Med Commun; 2002 Feb; 23(2):121-30. PubMed ID: 11891465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.
    Hellwig D; Ketter R; Romeike BF; Sell N; Schaefer A; Moringlane JR; Kirsch CM; Samnick S
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1041-9. PubMed ID: 15902439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[123I]iodo-phenylalanine.
    Bauwens M; Keyaerts M; Lahoutte T; Kersemans K; Caveliers V; Bossuyt A; Mertens J
    Nucl Med Commun; 2007 Oct; 28(10):823-8. PubMed ID: 17728613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI.
    von Forstner C; Zuhayra M; Ammerpohl O; Zhao Y; Tiwari S; Jansen O; Kalthoff H; Henze E; Egberts JH
    Hepatobiliary Pancreat Dis Int; 2011 Feb; 10(1):30-7. PubMed ID: 21269932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic mice.
    Kersemans V; De Spiegeleer B; Mertens J; Slegers G
    Nucl Med Biol; 2006 Jan; 33(1):119-23. PubMed ID: 16459267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-α-Methyl-Phenylalanine for Tumor PET Imaging.
    Hanaoka H; Ohshima Y; Suzuki Y; Yamaguchi A; Watanabe S; Uehara T; Nagamori S; Kanai Y; Ishioka NS; Tsushima Y; Endo K; Arano Y
    J Nucl Med; 2015 May; 56(5):791-7. PubMed ID: 25814518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.